Capital Guardian Trust’s iShares Biotechnology ETF IBB Stock Holding History

Capital Guardian Trust’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-75	Closed	-$9K	–	352
2018 Q3	$9K	Buy	+75	New	+$8.83K	﹤0.01%	468
2016 Q2	–	Sell	-450	Closed	-$39K	–	725
2016 Q1	$39K	Buy	+450	New	+$40.2K	﹤0.01%	454

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Capital Guardian Trust's IBB Position: Q4 2018 in Review

Capital Guardian Trust sold out of iShares Biotechnology ETF (IBB) in Q4 2018, closing a stake of 75 shares — an estimated $9K sold.

Capital Guardian Trust first reported a position in IBB in Q1 2016 and held it in 2 quarters. The position peaked at $39K in Q1 2016. 649 funds tracked by Wall St. Rank hold IBB as of Q4 2018.

Capital Guardian Trust reported no remaining iShares Biotechnology ETF position as of Q4 2018 after selling out during the quarter.
Capital Guardian Trust sold 75 iShares Biotechnology ETF shares in Q4 2018, an estimated $9K.
Capital Guardian Trust first reported a position in iShares Biotechnology ETF in Q1 2016 and held it in 2 quarters.
Capital Guardian Trust's iShares Biotechnology ETF position peaked at $39K in Q1 2016.
649 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2018.

Based on Capital Guardian Trust's 13F filing for Q4 2018, filed 14 Feb 2019.